Syria Conflict Squeezes Drug Supplies for Major Diseases, WHO Says
This article was originally published in PharmAsia News
Syria’s local production of medicines, once 90% of the nation’s consumption, has been greatly reduced by the civil war in the country, particularly in the provinces of Aleppo, Damascus and Homs where local drug makers tended to congregate.
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.